Cardiac Dysfunction Associated with Lacosamide in a Premature Infant with Hypoxic Ischemic Encephalopathy: A Case Report
Lacosamide (Vimpat Harris FRC Corporation, 2022 UCB, Inc. Smyrna, GA 30080) is an antiseizure medication, which acts through blockage of voltage-gated neuronal sodium channels. Its recent implementation in the neonatal population has been extrapolated from adult and pediatric data suggesting a favor...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Thieme Medical Publishers, Inc.,
2024-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lacosamide (Vimpat Harris FRC Corporation, 2022 UCB, Inc. Smyrna, GA 30080) is an antiseizure medication, which acts through blockage of voltage-gated neuronal sodium channels. Its recent implementation in the neonatal population has been extrapolated from adult and pediatric data suggesting a favorable safety profile. Of note, preterm infants have unique developmental characteristics that may predispose them to increased risk of adverse reactions. We present a case of a preterm neonate who developed left ventricular dysfunction coinciding with the initiation of lacosamide. |
|---|---|
| Item Description: | 2157-6998 2157-7005 10.1055/a-2447-8662 |